Prognostic factors in malignant mesothelioma

Lung Cancer

Volumn 45, Issue SUPPL., 2004, Pages

  Burgers, Jacobus A ^a   Damhuis, Ronald A M ^b  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b Integraal Kankercentrum Rotterdam   (Netherlands)

Author keywords

Anatomical staging; Biological markers; Mesothelioma; Performance status; Prognostic factors; Prognostic scoring systems

Indexed keywords

CANCER STAGING; CONFERENCE PAPER; HISTOLOGY; HUMAN; LEUKOCYTE COUNT; MALIGNANT MESOTHELIOMA; MOLECULAR DYNAMICS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; VALIDATION PROCESS; WEIGHT REDUCTION;

HEALTH STATUS; HUMANS; LEUKOCYTE COUNT; MESOTHELIOMA; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; WEIGHT LOSS;

EID: 3142782032     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.04.012     Document Type: Conference Paper

References (39)

1. Edwards J.G., Abrams K.R., Leverment J.N. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax. 55:2000;731-735
2. Curran D., Sahmoud T., Therasse P. Prognostic factors in patients with pleural mesothelioma: the European Organisation for research and treatment of cancer experience. J. Clin. Oncol. 16:1998;145-152
3. Gospodarowitcz MK, Henson DE, Hutter RVP, Prognostic factors in cancer. 2nd ed. New York: John Wiley & Sons, Inc.; 2001.
4. Herndon J.E., Green M.R., Chahinian A.P. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 113:1998;723-731
5. Steele J.P. Prognostic factors in mesothelioma. Semin. Oncol. 29:2002;36-40
6. Metintas M., Metintas S., Ucgun I. Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics. Respir. Med. 95:2001;829-835
7. Thylen A., Hjerpe A., Martensson G. Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma. Cancer. 92:2001;1224-1230
8. Rusch V.W., Venkatraman E.S. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann. Thorac. Surg. 68:1999;1799-1804
9. Boutin C., Rey F., Gouvernet J. Malignant mesothelioma: prognostic factors in a series of 125 patients studied from 1973 to 1987. Bull. Acad. Natl. Med. 176:1992;105-114. discussion 115-117
10. Sugarbaker D.J., Flores R.M., Jaklitsch M.T. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J. Thorac. Cardiovasc. Surg. 117:1999;54-63. discussion 63-65
11. Tammilehto L., Kivisaari L., Salminen U.S. Evaluation of the clinical TNM staging system for malignant pleural mesothelioma: an assessment in 88 patients. Lung Cancer. 12:1995;25-34
12. Pass H.I., Temeck B.K., Kranda K. Preoperative tumour volume is associated with outcome in malignant pleural mesotheliom. J. Thorac. Cardiov. Surg. 155:1998;310-317. discussion 317-318
13. Johansson L., Linden C.J. Aspects of histopathologic subtype as a prognostic factor in 85 pleural mesotheliomas. Chest. 109:1996;109-114
14. Ceresoli G.L., Locati L.D., Ferreri A.J. Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer. 34:2001;279-287
15. Merritt N., Blewett C.J., Miller J.D. Survival after conservative (palliative) management of pleural malignant mesothelioma. J. Surg. Oncol. 78:2001;171-174
16. British Thoracic Society Standards of Care Committee. Statement on malignant mesothelioma in the United Kingdom. Thorax 2001;56:250-65.
17. Takagi K., Tsuchiya R., Watanabe Y. Surgical approach to pleural diffuse mesothelioma in Japan. Lung Cancer. 31:2001;57-65
18. Spirtas R., Connelly R.R., Tucker M.A. Survival patterns for malignant mesothelioma: the SEER experience. Int. J. Cancer. 41:1988;525-530
19. Tiainen M., Tammilehto L., Rautonen J. Chromosomal abnormalities and their correlations with asbestos exposure and survival in patients with mesothelioma. Br. J. Cancer. 60:1989;618-626
20. Pyrhonen S., Laasonen A., Tammilehto L. Diploid predominance and prognostic significance of S-phase cells in malignant mesothelioma. Eur. J. Cancer. 27:1991;197-200
21. Isobe H., Sridhar K.S., Doria R. Prognostic significance of DNA aneuploidy in diffuse malignant mesothelioma. Cytometry. 19:1995;86-91
22. Beer T.W., Carr N.J., Whittaker M.A. Mitotic and in situ end-labeling apoptotic indices as prognostic markers in malignant mesothelioma. Ann. Diagn. Pathol. 4:2000;143-148
23. Emri S., Akbulut H., Zorlu F. Prognostic significance of flow cytometric DNA analysis in patients with malignant pleural mesothelioma. Lung Cancer. 33:2001;109-114
24. Kahlos K., Soini Y., Paakko P. Proliferation, apoptosis, and manganese superoxide dismutase in malignant mesothelioma. Int. J. Cancer. 88:2000;37-43
25. Beer T.W., Shepherd P., Pullinger N.C. p27 immunostaining is related to prognosis in malignant mesothelioma. Histopathology. 38:2001;535-541
26. Bongiovanni M., Cassoni P., De Giuli P. p27(kip1) immunoreactivity correlates with long-term survival in pleural malignant mesothelioma. Cancer. 92:2001;1245-1250
27. Leonardo E., Zanconati F., Bonifacio D. Immunohistochemical MIB-1 and p27kip1 as prognostic factors in pleural mesothelioma. Pathol. Res. Pract. 197:2001;253-256
28. Isik R., Metintas M., Gibbs A.R. p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure. Respir. Med. 95:2001;588-593
29. Di Muzio M., Spoletini L., Strizzi L. Prognostic significance of presence and reduplication of basal lamina in malignant pleural mesothelioma. Hum. Pathol. 31:2000;1341-1345
30. Edwards J.G., Cox G., Andi A. Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br. J. Cancer. 85:2001;863-868
31. Ohta Y., Shridhar V., Bright R.K. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br. J. Cancer. 81:1999;54-61
32. Kumar-Singh S., Jacobs W., Dhaene K. Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome. J. Pathol. 186:1998;300-305
33. Kumar-Singh S., Weyler J., Martin M.J. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J. Pathol. 189:1999;72-78
34. Dazzi H., Hasleton P.S., Thatcher N. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br. J. Cancer. 61:1990;924-926
35. Ohta Y., Shridhar V., Kalemkerian G.P. Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma. Cancer. 85:1999;2570-2576
36. Kahlos K., Soini Y., Sormunen R. Expression and prognostic significance of catalase in malignant mesothelioma. Cancer. 91:2001;1349-1357
37. Benard F., Sterman D., Smith R.J. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J. Nucl. Med. 40:1999;1241-1245
38. Procopio A., Strizzi L., Vianale G. Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma. Genes Chromosomes Cancer. 29:2000;173-179
39. Schouwink H., Korse C.M., Bonfrer J.M. Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma. Lung Cancer. 25:1999;25-32